Despite the absence of MHC class II molecules on tumor cells, stem-cell-like CD4+ T cells specific for tumor neoantigens can mediate profound antitumor effects by licensing antigen-presenting cells and augmenting antitumor CD8+ T cells in the tumor microenvironment and draining lymph nodes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sharma, P. et al. Cell 186, 1652–1669 (2023).
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Nat. Med. 28, 678–689 (2022).
Speiser, D. E., Chijioke, O., Schaeuble, K. & Munz, C. Nat. Cancer 4, 317–329 (2023).
Brightman, S. E. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01543-9 (2023).
Veatch, J. R. et al. Cancer Cell 40, 393–409 e399 (2022).
Oliveira, G. et al. Nature 605, 532–538 (2022).
Tran, E. et al. Science 344, 641–645 (2014).
Creelan, B. C. et al. Nat. Med. 27, 1410–1418 (2021).
Shakiba, M. et al. J. Exp. Med. 219 (2022).
Ferris, S. T. et al. Nature 584, 624–629 (2020).
Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Nat. Rev. Cancer. 12, 671–684 (2012).
Huang, Q. et al. Cell 185, 4049–4066 e4025 (2022).
Poncette, L., Bluhm, J. & Blankenstein, T. Curr. Opin. Immunol. 74, 18–24 (2022).
Acknowledgements
This work was supported by US National Institutes of Health grants P50 CA228944 (S.R.R., J.R.V.) and R01 CA114536 (S.R.R.) and Department of Defense grants W81XWH-20-1-0239 and W81XWH-22-2-0006 (S.R.R.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.R.R. is a co-founder of and holds equity in Lyell Immunopharma. J.R.V. and S.R.R. have received grant funding from and have intellectual property licensed to Lyell Immunopharma. J.R.V. and S.R.R. have received research support from Bristol Myers Squibb.
Rights and permissions
About this article
Cite this article
Veatch, J.R., Riddell, S.R. Stem-cell-like CD4+ T cells prey on MHC class II–negative tumors. Nat Immunol 24, 1212–1214 (2023). https://doi.org/10.1038/s41590-023-01563-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01563-5
